EFDID: 355592EFD: View Filing

Issuer: Summit Therapeutics Inc. (0001599298) - D

Accession: 0001599298-20-000044 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001599298
  • Entity Name:
    Summit Therapeutics Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2020)
  • Address:
    ONE BROADWAY
    14TH FLOOR
    CAMBRIDGE, MA 02142
  • Persons:
    Related Persons 9
    Robert Duggan
    Executive Officer 
    Mr. Duggan is the Issuer's Chief Executive Officer and Executive Chairman and was one of three investors in the offering.
    Mahkam Zanganeh
    Director
    Rainer Erdtmann
    Director
    Manmeet Soni
    Director
    Ujwala Mahatme
    Director
    Michael Paul Donaldson
    Executive Officer
    Houbiers Jos
    Executive Officer
    David Johnathan Powell
    Executive Officer
    Camilla Graham
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    11/20/2020
  • First Sale Date:
    11/06/2020
  • Offering Amount:
    $50,000,000
  • Amount Sold:
    $50,000,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information

There were no Sales Compensation Recipient Information associated with this Accession Number.

EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Summit Therapeutics Inc./s/Michael DonaldsonMichael DonaldsonChief Financial Officer2020-11-20